RESUMEN
ObjectiveTo observe the clinical efficacy of modified Tuoli Xiaodusan （TLXDS） in adjuvant treatment of Helicobacter pylori （Hp）-positive peptic ulcer （PU） with cold-heat complex syndrome and explore its regulating effect on invasive/protective factors. MethodA total of 136 patients were randomly assigned into the control group （68 cases， including 4 cases missing， 3 cases eliminated， and 61 cases completed） and the TLXDS group （68 cases， including 4 cases missing， 1 case eliminated， and 63 cases completed）. Both groups adopted the quadruple therapy of acid suppression and Hp eradication. The patients in the control group received Weinai'an capsules orally at 4 capsules/time and 3 times/day， and those in the TLXDS group took modified TLXDS orally at 1 dose/day. The administration of both groups lasted for 8 consecutive weeks and the follow-up lasted for 12 months. Electronic gastroscopy was carried out before and after treatment for evaluating the healing of ulcer， the score of mucosal morphology， and the maturity of regenerated mucosa. The Hp infection and the score of cold-heat complex syndrome were evaluated before and after treatment. The serum levels of gastrin （GAS）， prostaglandin E2 （PGE2）， pepsinogen （PG）-Ⅰ， PG-Ⅱ， epidermal growth factor （EGF）， and trefoil factor 2 （TFF-2） were determined before and after therapy. The recurrence of Hp and PU was recorded， and the drug safety was evaluated. ResultAfter treatment， the mucosal morphology score and the traditional Chinese medicine （TCM） syndrome score in the TLXDS group were lower than those in the control group （P<0.01）. The levels of GAS， PG-Ⅰ， and PG-Ⅱ in the TLXDS group were lower than those in the control group （P<0.01）， whereas those of PGE2， EGF， and TFF-2 showed an opposite trend （P<0.01）. After treatment， the Hp eradication rate in the TLXDS group was 95.24% （60/63）， higher than that （83.61%， 51/61） in the control group （χ2=4.467， P<0.05）. The total effective rate of TCM syndromes in the TLXDS group was 98.41% （62/63）， higher than that （81.97%， 50/61） in the control group （χ2=9.589， P<0.01）. The total effective rate of the TLXDS group under gastroscopy was 98.41% （62/63）， higher than that （86.89%， 53/61） in the control group （χ2=4.525， P<0.05）. The excellent and good rate of regenerated mucosal maturity in the TLXDS group was 92.06% （58/63）， also higher than that （73.77%， 45/61） in the control group （χ2=7.372， P<0.01）. After 12 months of follow-up， the TLXDS group had lower PU recurrence rate ［19.05% （12/63） vs 37.70% （23/61）， χ2=5.325， P<0.05］ and lower Hp recurrence rate ［15.00% （9/60） vs 33.33% （17/51）， χ2=5.165， P<0.05） than the control group. No adverse reactions related to TLXDS were detected. ConclusionModified TLXDS-assisted quadruple therapy demonstrates significant short-term clinical efficacy and high Hp eradication rate for Hp-positive PU （cold-heat complex syndrome） patients. Moreover， it can adjust the levels of invasive/protective factors to facilitate ulcer healing and reduce the recurrence rates of Hp and PU in a long term， with good clinical safety.
RESUMEN
[Objective]To explore the experiences of professor ZHENG Qizhong to use classical prescription treating the cold-heat complex pediatric diseases.[Method]By following professor ZHENG Qizhong, gathering the cases that are all treated by professor ZHENG Qizhong to treat pneumonia asthma case using Xiao Qinglong Decoction plus Shigao, abdominal pain and diarrhoea cases using Banxia Xiexin Decoction, diarrhoea and pertussis cases using Wumei pill, pneumonia asthma accompanied by diarrhea case using Mahuang Shengma decoction, analysing the mechanism of the upper prescription and the clinical experiences of treating cold -heat complex paediatric diseases. [Results] Cold -heat complex paediatric diseases are very common in paediatric acute or chronic diseases, professor ZHENG Qizhong has an original idea and in -depth study of classical prescription, and using them flexibly to treat various paediatric diseases such as pneumonia asthma, abdominal pain, diarrhea, pertussis, etc, and always acquires good results. [Conclusion]The clinical experiences of ZHENG Qizhong using the classical prescription to treat Cold-heat Complex Paediatric Diseases is effective and has the value to study, popularization and application.
RESUMEN
Objective To observe the clinical curative effect of Wumei Pill in the treatment of cold-heat complex diarrhea-predominant irritable bowel syndrome.Methods Modified Wumei Pill was adopted to treat 46 cases of cold-heat complex diarrhea predominant irritable bowel syndrome.Five main symptoms of stool frequency,stool shape and properties,abdominal pain and discomfort,bowel gurgling,vulnerable to the cold were observed.The symptom scores before the treatment and 1 week,2 weeks and 4 weeks after the treatment were evaluated.Results After the treatment of 1 week,2 weeks and 4 weeks,the overall efficiency was 58.70％(27/46),84.78％(39/46),and 97.83％(45/46) respectively,and there were significant differences in curative effect between the different treatment courses (between treatment of 2 weeks and 1 weekx2＝8.571,between treatment of 4 weeks and 2 weekx2=16.426,between treatment of 4 weeks and 1 week x2=35.622).Effective rate of symptoms after 4 weeks treatment were respectively:stool frequency 82.05％ (32/39),stool shape and properties 95.56％ (43/45),abdominal pain and discomfort 92.86％ (39/42),bowel gurgling 85.71％ (18/21),vulnerable to the cold 64.29％ (27/42),and there was obvious differences in effective percentage of five kinds of symptoms between treatment of 4 weeks and 1 week (Stool frequency x2 =7.123、stool shape and properties x2 =13.611、abdominal pain or discomfort x2 =7.721、bowel gurgling x2=10.096、vulnerable to the cold x2=10.769).Conclusion.The clinical effect of Wumei Pill for the treatment of cold-heat complex diarrhea predominant irritable bowel syndrome was defined.